Chang W, Zhu F, Zheng H, Zhou Z, Miao P, Zhao L, Mao Z
The addition of AMPLITUDE-O data refined evidence for cardiovascular benefits, in particular showing reduction in hospital admission for heart failure, and suggested exendin-4-based compounds lower risks as well as human-based GLP-1 receptor agonists, Naveed Sattar, MD, PhD, professor of metabolic medicine at the University of Glasgow in the U.K., and colleagues wrote
The longest anyone was treated in any of them is two weeks
GLP-1 is an incretin hormone produced by intestinal L-cells that stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and promotes satiety in response to food intake